⌘K
Loading ticker…
As of 2026-08-24, Inovio Pharmaceuticals, Inc. (INO) has a 3-month relative strength percentile of 34 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 11.3%, relative volume 0.69×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
INO is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $4M notional.
Held by 3 ETFs · $5M across latest filings · largest weight 0.02% (IWC).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $4M | — |
| VXFVanguard Extended Market ETF | 0.00% | $1M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | INO Jan avg: 0.59% median: 0.04% win: 50% σ: 11.88% n: 4 2022-04-12 → 2026-07-31 | INO Feb avg: 11.52% median: 2.89% win: 50% σ: 38.05% n: 4 2022-04-12 → 2026-07-31 | INO Mar avg: 0.05% median: -10.77% win: 25% σ: 39.82% n: 4 2022-04-12 → 2026-07-31 | INO Apr avg: -10.76% median: -13.88% win: 20% σ: 19.91% n: 5 2022-04-12 → 2026-07-31 | INO May avg: -9.10% median: -11.53% win: 40% σ: 19.46% n: 5 2022-04-12 → 2026-07-31 | INO Jun avg: -13.48% median: -16.03% win: 20% σ: 10.75% n: 5 2022-04-12 → 2026-07-31 | INO Jul avg: -0.63% median: 14.45% win: 60% σ: 31.56% n: 5 2022-04-12 → 2026-07-31 | INO Aug avg: 8.71% median: 0.11% win: 50% σ: 43.58% n: 4 2022-04-12 → 2026-07-31 (current) | INO Sep avg: -14.85% median: -16.74% win: 0% σ: 10.14% n: 4 2022-04-12 → 2026-07-31 | INO Oct avg: 2.66% median: -2.96% win: 50% σ: 15.52% n: 4 2022-04-12 → 2026-07-31 | INO Nov avg: -6.97% median: -8.95% win: 25% σ: 11.36% n: 4 2022-04-12 → 2026-07-31 | INO Dec avg: -16.83% median: -19.53% win: 25% σ: 35.81% n: 4 2022-04-12 → 2026-07-31 |